Recombinant Human CD19 protein, His-tagged, Site-Specific AF 647-Labeled

• Cat.No.: CD19-2948H
• Product Overview: Recombinant Human CD19 protein (Met1-Lys291)(P15391-1) was expressed in HEK293 Stable Cells with a C-terminal polyhistidine tag. The protein is site-specifically conjugated with AF 647 (Excitation Max.= 655 nm, Emission Max.= 680 nm).

Specification

• Source: HEK293 Stable Cells
• Species: Human
• Tag: C-His
• Protein length: Met1-Lys291
• Form: This product is Lyophilized from sterile PBS, pH 7.4, with 5 %-8 % trehalose.
• Molecular Mass: The protein has a predicted molecular mass of 31.6 kDa.
• Endotoxin: < 1.0 EU per μg protein as determined by the LAL method.
• Storage: Twelve months from date of receipt at -20°C to -70°C in lyophilized form and 3 months at -70°C under sterile conditions after reconstitution. Protect from prolonged exposure to light and avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: CD19 CD19 molecule [ Homo sapiens ]
• Official Symbol: CD19
• Synonyms: CD19; CD19 molecule; CD19 antigen; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4; B4; CVID3; MGC12802
• Gene ID: 930
• mRNA Refseq: NM_001178098
• Protein Refseq: NP_001171569
• MIM: 107265
• UniProt ID: P15391

Reviews

01/02/2023

The manufacturer of CD19 protein has consistently provided outstanding technical support that has surpassed my expectations.

08/18/2022

This protein demonstrates remarkable purity, stability, and specificity, ensuring utmost accuracy and reproducibility in my research endeavors.

06/29/2016

Their dedication to customer satisfaction has been instrumental in overcoming obstacles and achieving successful results in my experiments.

Q&As

How does CAR-T cell therapy work to combat CD19-expressing cancers?

CAR-T cells are engineered to express a receptor that recognizes CD19 on the surface of cancerous B cells. When they encounter these cells, they destroy them.

Are there any diseases associated with CD19 dysfunction?

CD19 deficiencies can lead to primary immunodeficiencies, making individuals more susceptible to infections.

What are the potential side effects of CAR-T cell therapy targeting CD19?

Side effects may include cytokine release syndrome (CRS), neurologic toxicity, and long-term B-cell aplasia.

What are some CD19-expressing malignancies that CAR-T cell therapy can target?

CAR-T cell therapy is used to treat B-cell malignancies such as acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma.

How effective is CAR-T cell therapy in treating CD19-expressing cancers?

CAR-T cell therapy has shown remarkable effectiveness in inducing remissions in patients with CD19-positive malignancies, particularly in those who have relapsed or failed conventional treatments.